Proteus Biomedical Inc. wins CE Mark approval to market its ingestible sensor and personal physiologic monitor system in the European Union.

European Union doctors may now begin prescribing Proteus Biomedical Inc.'s "Raisins."
The Redwood City, Calif.-based company won CE Mark approval for its ingestible "Raisin" sensor and personal physiologic monitor system.
Proteus also announced ISO 13485:2003 certification for the system, according to a press release.
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-...
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for...